Drug Dev
TikoMed platform boosts regenerative stem cell therapy outcomes
A major challenge for stem cell therapy is an innate immunity reaction that kills off about 50% of transplanted cells. TikoMed founder and CEO Adam Bruce talked to Scrip during BIO-Europe Spring about how the company's IBsolvMIR platform, which is in Phase II studies, has the potential to improve the viability of cells prior to transplantation.